130 related articles for article (PubMed ID: 34089835)
1. Metabolism of oral turinabol by the human brain cholesterol 24-hydroxylase CYP46A1.
Putkaradze N; Hartz P; Hutter MC; Zapp J; Thevis M; Bernhardt R
J Steroid Biochem Mol Biol; 2021 Sep; 212():105927. PubMed ID: 34089835
[TBL] [Abstract][Full Text] [Related]
2.
Mast N; Anderson KW; Johnson KM; Phan TTN; Guengerich FP; Pikuleva IA
J Biol Chem; 2017 Aug; 292(31):12934-12946. PubMed ID: 28642370
[TBL] [Abstract][Full Text] [Related]
3. Combined chemical and biotechnological production of 20βOH-NorDHCMT, a long-term metabolite of Oral-Turinabol (DHCMT).
Liu J; Chen L; Joseph JF; Naß A; Stoll A; de la Torre X; Botrè F; Wolber G; Parr MK; Bureik M
J Inorg Biochem; 2018 Jun; 183():165-171. PubMed ID: 29544993
[TBL] [Abstract][Full Text] [Related]
4. Cholesterol 24-Hydroxylation by CYP46A1: Benefits of Modulation for Brain Diseases.
Petrov AM; Pikuleva IA
Neurotherapeutics; 2019 Jul; 16(3):635-648. PubMed ID: 31001737
[TBL] [Abstract][Full Text] [Related]
5. Mapping of the Allosteric Site in Cholesterol Hydroxylase CYP46A1 for Efavirenz, a Drug That Stimulates Enzyme Activity.
Anderson KW; Mast N; Hudgens JW; Lin JB; Turko IV; Pikuleva IA
J Biol Chem; 2016 May; 291(22):11876-86. PubMed ID: 27056331
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of Oral Turinabol by Human Steroid Hormone-Synthesizing Cytochrome P450 Enzymes.
Schiffer L; Brixius-Anderko S; Hannemann F; Zapp J; Neunzig J; Thevis M; Bernhardt R
Drug Metab Dispos; 2016 Feb; 44(2):227-37. PubMed ID: 26658226
[TBL] [Abstract][Full Text] [Related]
7. Cholesterol 24-hydroxylase: Brain cholesterol metabolism and beyond.
Moutinho M; Nunes MJ; Rodrigues E
Biochim Biophys Acta; 2016 Dec; 1861(12 Pt A):1911-1920. PubMed ID: 27663182
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Dicaffeoylspermidine Derivatives from Wolfberry as Potent and Selective Inhibitors of Human Cytochrome P450 46A1
Du J; Liu J; Wang S; Wang C; Meng Q; Sun H; Liu K; Liu Y; Wu J
Curr Drug Metab; 2023; 24(2):124-130. PubMed ID: 36748817
[TBL] [Abstract][Full Text] [Related]
9. In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.
Mast N; Verwilst P; Wilkey CJ; Guengerich FP; Pikuleva IA
J Med Chem; 2020 Jun; 63(12):6477-6488. PubMed ID: 31617715
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional and post-translational changes in the brain of mice deficient in cholesterol removal mediated by cytochrome P450 46A1 (CYP46A1).
Mast N; Lin JB; Anderson KW; Bjorkhem I; Pikuleva IA
PLoS One; 2017; 12(10):e0187168. PubMed ID: 29073233
[TBL] [Abstract][Full Text] [Related]
11. Metabolic studies of turinabol in horses.
Ho EN; Kwok WH; Leung DK; Wan TS; Wong AS
Anal Chim Acta; 2007 Mar; 586(1-2):208-16. PubMed ID: 17386713
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic implications of altered cholesterol homeostasis mediated by loss of CYP46A1 in human glioblastoma.
Han M; Wang S; Yang N; Wang X; Zhao W; Saed HS; Daubon T; Huang B; Chen A; Li G; Miletic H; Thorsen F; Bjerkvig R; Li X; Wang J
EMBO Mol Med; 2020 Jan; 12(1):e10924. PubMed ID: 31777202
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 27A1 Deficiency and Regional Differences in Brain Sterol Metabolism Cause Preferential Cholestanol Accumulation in the Cerebellum.
Mast N; Anderson KW; Lin JB; Li Y; Turko IV; Tatsuoka C; Bjorkhem I; Pikuleva IA
J Biol Chem; 2017 Mar; 292(12):4913-4924. PubMed ID: 28190002
[TBL] [Abstract][Full Text] [Related]
14. Brain Acetyl-CoA Production and Phosphorylation of Cytoskeletal Proteins Are Targets of CYP46A1 Activity Modulation and Altered Sterol Flux.
Mast N; Petrov AM; Prendergast E; Bederman I; Pikuleva IA
Neurotherapeutics; 2021 Jul; 18(3):2040-2060. PubMed ID: 34235635
[TBL] [Abstract][Full Text] [Related]
15. Solid forms and β-cyclodextrin complexation of turinabol.
Turza A; Ulici A; Muresan-Pop M; Borodi G
Acta Crystallogr C Struct Chem; 2022 May; 78(Pt 5):305-313. PubMed ID: 35510437
[TBL] [Abstract][Full Text] [Related]
16. Combined use of mass spectrometry and heterologous expression for identification of membrane-interacting peptides in cytochrome P450 46A1 and NADPH-cytochrome P450 oxidoreductase.
Mast N; Liao WL; Pikuleva IA; Turko IV
Arch Biochem Biophys; 2009 Mar; 483(1):81-9. PubMed ID: 19161969
[TBL] [Abstract][Full Text] [Related]
17. Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain.
Mast N; White MA; Bjorkhem I; Johnson EF; Stout CD; Pikuleva IA
Proc Natl Acad Sci U S A; 2008 Jul; 105(28):9546-51. PubMed ID: 18621681
[TBL] [Abstract][Full Text] [Related]
18. GC and capillary column GC/MS determination of synthetic anabolic steroids. II. 4-chloro-methandienone (oral turinabol) and its metabolites.
Dürbeck HW; Büker I; Scheulen B; Telin B
J Chromatogr Sci; 1983 Sep; 21(9):405-10. PubMed ID: 6630400
[TBL] [Abstract][Full Text] [Related]
19. The Hydroxylation Position Rather than Chirality Determines How Efavirenz Metabolites Activate Cytochrome P450 46A1 In Vitro.
Mast N; Fotinich A; Pikuleva IA
Drug Metab Dispos; 2022 Jul; 50(7):923-930. PubMed ID: 35489779
[TBL] [Abstract][Full Text] [Related]
20. Marked change in the balance between CYP27A1 and CYP46A1 mediated elimination of cholesterol during differentiation of human neuronal cells.
Milagre I; Olin M; Nunes MJ; Moutinho M; Lövgren-Sandblom A; Gama MJ; Björkhem I; Rodrigues E
Neurochem Int; 2012 Jan; 60(2):192-8. PubMed ID: 22185844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
